Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ONMDW | 8-K | neutral | 3/10 | OneMedNet Corp filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders held on September 18, 2026. | Sep 23, 2026 |
| KRSA | 144 | neutral | 2/10 | Director Errol B. De Souza filed a Form 144 to sell 4,903 shares of Korsana Biosciences common stock, with an approximat | Sep 23, 2026 |
| TEVA | PRESS-RELEASE | neutral | 2/10 | Teva published its Q3 2026 Aide Memoire, a compilation of previously disclosed public information, ahead of its Q3 earni | Sep 23, 2026 |
| TEVA | PRESS-RELEASE | neutral | 1/10 | Teva Pharmaceutical Industries Ltd announced it will host a conference call on November 3, 2026 to discuss its Q3 2026 r | Sep 23, 2026 |
| QDEL | 8-K | bearish | 6/10 | QuidelOrtho amended its existing credit agreement to reset financial covenant levels through a 'Covenant Relief Period' | Sep 23, 2026 |
| TBPH | 25-NSE | bearish | 7/10 | The Nasdaq Stock Market LLC filed a Form 25-NSE to report the removal from listing and registration of Theravance Biopha | Sep 23, 2026 |
| PULM | S-4/A | neutral | 2/10 | Pulmatrix filed Amendment No. 4 to its S-4 registration statement for the proposed merger with Eos SENOLYTIX, Inc. This | Sep 23, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt and EVP Paul Mahon executed a cluster of open-market sales totaling ~$14.8M over Sept 17-21, 2026. | Sep 23, 2026 |
| NRIX | SC 13G | neutral | 3/10 | Perceptive Advisors LLC, a healthcare-focused investment firm, filed a Schedule 13G disclosing a 5.3% passive stake in N | Sep 23, 2026 |
| ZYME | PRESS-RELEASE | bullish | 6/10 | Zymeworks completed its acquisition of Theravance Biopharma, adding YUPELRI and TRELEGY royalty streams to its portfolio | Sep 23, 2026 |
| OPTH | 6-K | neutral | 3/10 | Optimi Health completed a cGMP production batch of 5mg psilocybin capsules to supply both a Health Canada-approved Phase | Sep 23, 2026 |
| CRDL | SC 13G/A | bullish | 5/10 | Tejara Capital Ltd filed an amended Schedule 13G disclosing a 5.3% passive stake in Cardiol Therapeutics Inc. as of Sept | Sep 23, 2026 |
| ADTX | 8-K | bearish | 8/10 | Nasdaq has formally announced it will file a Form 25 with the SEC to complete the delisting of Aditxt's common stock, ef | Sep 23, 2026 |
| PHVS | CLUSTER | bearish | 6/10 | A massive insider selling cluster at Pharvaris: 9 insiders sold ~$14.4M in open-market sales within a week, including th | Sep 23, 2026 |
| GRML | 424B5 | bullish | 4/10 | Greenland Mines Ltd filed a 424B5 prospectus supplement to suspend its ATM sales agreement with A.G.P./Alliance Global P | Sep 23, 2026 |
| TECH | PRESS-RELEASE | bullish | 6/10 | Bio-Techne shareholders voted to approve the acquisition by Merck KGaA, Darmstadt, Germany. The HSR waiting period has e | Sep 23, 2026 |
| BCDA | 8-K | neutral | 3/10 | BioCardia filed an 8-K providing a routine update on regulatory timelines for its CardiAMP HF and Helix programs. The co | Sep 23, 2026 |
| BCDA | PRESS-RELEASE | neutral | 4/10 | BioCardia provided a regulatory milestone update, highlighting a planned Q4 2026 Shonin pre-market submission to Japan's | Sep 23, 2026 |
| SPRC | PRESS-RELEASE | neutral | 3/10 | SciSparc announced that its majority-owned subsidiary NeuroThera, through its collaboration with Clearmind Medicine, has | Sep 23, 2026 |
| GRML | PRESS-RELEASE | neutral | 2/10 | Greenland Mines Ltd. was featured in an editorial by MiningNewsWire discussing rising demand for rare earth and critical | Sep 23, 2026 |
| MBRX | 8-K | mixed | 5/10 | Moleculin Biotech announced the grant of Mexican Patent No. 436849 protecting its lung-targeted liposomal Annamycin tech | Sep 23, 2026 |
| CORT | 8-K | neutral | 3/10 | Corcept announced the retirement of Sean Maduck, President of Endocrinology, effective October 1, 2026, with Justin Gunn | Sep 23, 2026 |
| MGTX | 8-K | neutral | 2/10 | MeiraGTx appointed Alan M. Sebulsky, a veteran healthcare portfolio manager with over 40 years of experience, to its Boa | Sep 23, 2026 |
| CMND | 6-K | neutral | 3/10 | Clearmind Medicine announced the U.S. publication of three patent applications covering novel combinations of LSD, ketam | Sep 23, 2026 |
| PRQR | 6-K | neutral | 4/10 | ProQR announced the appointment of Chris Hart (ex-Eli Lilly VP of Data Science) as Chief Data and AI Officer and Thomas | Sep 23, 2026 |
| CMND | PRESS-RELEASE | neutral | 3/10 | Clearmind Medicine announced the U.S. publication of three patent applications covering novel combinations of LSD, ketam | Sep 23, 2026 |
| LTRN | 8-K | neutral | 3/10 | Lantern Pharma filed an 8-K to announce a live webinar on September 23, 2026, presenting the growth plan for its Open-Me | Sep 23, 2026 |
| ARMP | 8-K | bullish | 5/10 | Armata Pharmaceuticals received $3.7 million in additional non-dilutive funding from the U.S. Department of War to suppo | Sep 23, 2026 |
| BMEA | PRESS-RELEASE | bullish | 5/10 | Biomea Fusion terminated its proposed public offering due to unfavorable market conditions, with no securities sold. Thi | Sep 23, 2026 |
| PBM | 6-K | bearish | 6/10 | Psyence Biomedical announced a strategic ibogaine investment package including a cash investment of up to US$5 million i | Sep 23, 2026 |